AN2 Therapeutics annual stock-based compensation
2021
2022
2023
2024
2025
AN2 Therapeutics Stock-Based Compensation Growth & History (ANTX)
AN2 Therapeutics's stock-based compensation was $6.2M for fiscal 2025.
View full AN2 Therapeutics company overviewAN2 Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.2M | −$2.1M | −25.09% |
| 2024 | 2024-12-31 | $8.3M | −$74,000 | −0.88% |
| 2023 | 2023-12-31 | $8.4M | $4.0M | +91.57% |
| 2022 | 2022-12-31 | $4.4M | $3.4M | +350.82% |
| 2021 | 2021-12-31 | $974,000 | — | — |
AN2 Therapeutics quarterly stock-based compensation
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $972,000 | −$1.0M | −51.35% |
| Q1 2026 | 2026-03-31 | $1.5M | −$587,000 | −28.68% |
| Q4 2025 | 2025-12-31 | $1.4M | −$380,000 | −21.35% |
| Q3 2025 | 2025-09-30 | $801,000 | −$1.1M | −57.89% |
| Q2 2025 | 2025-06-30 | $2.0M | −$273,000 | −12.02% |
| Q1 2025 | 2025-03-31 | $2.0M | −$338,000 | −14.17% |
| Q4 2024 | 2024-12-31 | $1.8M | −$452,000 | −20.25% |
| Q3 2024 | 2024-09-30 | $1.9M | −$267,000 | −12.31% |
| Q2 2024 | 2024-06-30 | $2.3M | $328,000 | +16.88% |
| Q1 2024 | 2024-03-31 | $2.4M | $317,000 | +15.33% |
| Q4 2023 | 2023-12-31 | $2.2M | $760,000 | +51.63% |
| Q3 2023 | 2023-09-30 | $2.2M | $941,000 | +76.63% |
| Q2 2023 | 2023-06-30 | $1.9M | $701,000 | +56.44% |
| Q1 2023 | 2023-03-31 | $2.1M | $1.6M | +360.58% |
| Q4 2022 | 2022-12-31 | $1.5M | $1.0M | +239.95% |
| Q3 2022 | 2022-09-30 | $1.2M | $874,000 | +246.89% |
| Q2 2022 | 2022-06-30 | $1.2M | $1.1M | +593.85% |
| Q1 2022 | 2022-03-31 | $449,000 | $441,000 | +5512.50% |
| Q4 2021 | 2021-12-31 | $433,000 | — | — |
| Q3 2021 | 2021-09-30 | $354,000 | — | — |
| Q2 2021 | 2021-06-30 | $179,000 | — | — |
| Q1 2021 | 2021-03-31 | $8,000 | — | — |
AN2 Therapeutics stock-based compensation trends
Between the periods ended 2021-12-31 and 2025-12-31, AN2 Therapeutics's stock-based compensation increased from $974,000 to $6.2M, a change of $5.3M. The latest reported quarter, Q2 2026, shows $972,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AN2 Therapeutics source filings ↗